Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

A Population-Based Compar… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden

Artikel i vetenskaplig tidskrift
Författare K. Isaksson
Dimitrios Katsarelias
R. Mikiver
A. Carneiro
Lars Ny
Roger Olofsson Bagge
Publicerad i Annals of Surgical Oncology
Volym 26
Nummer/häfte 9
Sidor 2839-2845
ISSN 1068-9265
Publiceringsår 2019
Publicerad vid Wallenberglaboratoriet
Institutionen för kliniska vetenskaper, Avdelningen för kirurgi
Sidor 2839-2845
Språk en
Länkar dx.doi.org/10.1245/s10434-019-07448...
Ämnesord american joint committee, sentinel-node biopsy, long-term survival, united-states, high-risk, thin, ipilimumab, phase-3, metastasis, dissection, Oncology, Surgery
Ämneskategorier Cancer och onkologi

Sammanfattning

Background Cutaneous melanoma is steadily increasing worldwide. The new AJCC 8th edition was recently launched and introduced several changes in melanoma staging, particularly for stage III. We conducted a population-based registry study with the purpose to evaluate the impact and prognostic accuracy of the new classification in Sweden. Methods Consecutive patients diagnosed with stage III melanoma between January 2005 and September 2017 were identified by the Swedish Melanoma Registry (SMR) and included for analyses. Patients with multiple primary melanomas were excluded. Patients were classified according to the AJCC 7th as well as the 8th edition. Melanoma-specific survival (MSS) was retrieved from the Swedish Cause of Death Registry. Results A total of 2067 eligible patients were identified from the SMR; 1150 patients (57%) changed stage III subgroup when reclassified according to the AJCC 8th edition. The median 5- and 10-year MSS for the whole cohort of stage III melanoma patients was 59% and 51% respectively. The MSS for substage IIIA, B, and C were all improved when patients were reclassified by using to the AJCC 8th edition. The newly defined substage IIID had the worst prognosis with a 10-year MSS of 16%. Conclusions A high proportion of patients diagnosed with stage III melanoma in Sweden between 2005 and 2017 was restaged to another subgroup, when they were reclassified according to the AJCC 8th of staging manual. We established an improved MSS for all substages compared with the former AJCC 7th edition. This may have implications on decisions about adjuvant treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?